Researches and develops novel therapies for Parkinson's disease (PD) and Alzheimer's disease (AD). Now — the numbers.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Trading Liquidity: The shares change hands too rarely for smooth trading.
An investor who bought at the very peak is down 96% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
We do not hold enough financial data on this company to point to a strength.
This stock swings about 456.6 times as much as the market average. Big rallies — and big drops — can both happen fast.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 0/10.
Getting in and out without moving the price could prove difficult. Council score: 2/10.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: revenue and profit, the growth trend, the balance sheet, earnings execution, the revenue breakdown.